These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10566084)

  • 1. HIV vaccine vCP205. ALVAC-HIV vCP205, ALVAC vCP205.
    Drugs R D; 1999 Jun; 1(6):459-60. PubMed ID: 10566084
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV gp120 vaccine (Chiron).
    Drugs R D; 1999 Jun; 1(6):445-7. PubMed ID: 10566078
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV gp120 vaccine gene therapy (Wyeth-Lederle Vaccines-Malvern).
    Drugs R D; 1999 Jun; 1(6):448. PubMed ID: 10566079
    [No Abstract]   [Full Text] [Related]  

  • 4. HIV gp160 vaccine (Immuno AG).
    Drugs R D; 1999 Jun; 1(6):449-50. PubMed ID: 10566080
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.
    Salmon-Céron D; Excler JL; Finkielsztejn L; Autran B; Gluckman JC; Sicard D; Matthews TJ; Meignier B; Valentin C; El Habib R; Blondeau C; Raux M; Moog C; Tartaglia J; Chong P; Klein M; Milcamps B; Heshmati F; Plotkin S
    AIDS Res Hum Retroviruses; 1999 May; 15(7):633-45. PubMed ID: 10331442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV vaccine AIDSVAX.
    Drugs R D; 1999 Jun; 1(6):456-8. PubMed ID: 10566083
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.
    Gupta K; Hudgens M; Corey L; McElrath MJ; Weinhold K; Montefiori DC; Gorse GJ; Frey SE; Keefer MC; Evans TG; Dolin R; Schwartz DH; Harro C; Graham B; Spearman PW; Mulligan M; Goepfert P;
    J Acquir Immune Defic Syndr; 2002 Mar; 29(3):254-61. PubMed ID: 11873074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV gp160 vaccine gene therapy (Wyeth-Lederle Vaccines-Malvern).
    Drugs R D; 1999 Jun; 1(6):451-2. PubMed ID: 10566081
    [No Abstract]   [Full Text] [Related]  

  • 9. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
    Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
    PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers.
    Gorse GJ; Patel GB; Belshe RB;
    AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1175-89. PubMed ID: 11522187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
    Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
    J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between env-specific T-cell epitopic responses in HIV-1-uninfected adults immunized with combination of ALVAC-HIV(vCP205) plus or minus rgp160MN/LAI-2 and HIV-1-infected adults.
    Ratto-Kim S; Loomis-Price LD; Aronson N; Grimes J; Hill C; Williams C; El Habib R; Birx DL; Kim JH
    J Acquir Immune Defic Syndr; 2003 Jan; 32(1):9-17. PubMed ID: 12514409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AIDS vaccine: efficacy, safety and ethics.
    Veljkovic V; Veljkovic N; Glisic S; Ho MW
    Vaccine; 2008 Jun; 26(24):3072-7. PubMed ID: 18164521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women.
    Johnson DC; McFarland EJ; Muresan P; Fenton T; McNamara J; Read JS; Hawkins E; Bouquin PL; Estep SG; Tomaras GD; Vincent CA; Rathore M; Melvin AJ; Gurunathan S; Lambert J
    J Infect Dis; 2005 Dec; 192(12):2129-33. PubMed ID: 16288378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 envelope-specific cytotoxic T lymphocytes response dynamics after prime-boost vaccine regimens with human immunodeficiency virus type 1 canarypox and pseudovirions.
    Arp J; Rovinski B; Sambhara S; Tartaglia J; Dekaban G
    Viral Immunol; 1999; 12(4):281-96. PubMed ID: 10630788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV vaccines. Viral envelope fails to deliver?
    Bolognesi DP; Matthews TJ
    Nature; 1998 Feb; 391(6668):638-9. PubMed ID: 9490406
    [No Abstract]   [Full Text] [Related]  

  • 18. Approaches to preventative and therapeutic HIV vaccines.
    Gray GE; Laher F; Lazarus E; Ensoli B; Corey L
    Curr Opin Virol; 2016 Apr; 17():104-109. PubMed ID: 26985884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine to prevent AIDS overstated.
    Lewis D
    Res Initiat Treat Action; 1999 Jan; 5(1):11-2. PubMed ID: 11366223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.
    O'Connell RJ; Excler JL; Polonis VR; Ratto-Kim S; Cox J; Jagodzinski LL; Liu M; Wieczorek L; McNeil JG; El-Habib R; Michael NL; Gilliam BL; Paris R; VanCott TC; Tomaras GD; Birx DL; Robb ML; Kim JH
    J Infect Dis; 2016 Jun; 213(12):1946-54. PubMed ID: 26908741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.